$VNRX

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. vnrx_8k.htm 0000093314 false 0000093314 2026-08-06 2026-08-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 D

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. vnrx_8k.htm 0000093314 false --12-31 0000093314 2026-07-17 2026-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O

VolitionRx Limited (NYSE American: VNRX) said a real-world study with Hospices Civils de Lyon found its Nu.Q® Cancer assay (H3K27Me3-nucleosomes) in newly diagnosed lung cancer patients was associated with cancer stage and poorer outcomes. Volition reported an OS analysis using a cut-off and a Cox model stratifying low/high mortality risk, and said HCL clinical certification is complete and a France reimbursement dossier is planned.

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. vnrx_8k.htm 0000093314 false 0000093314 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 D

VolitionRx Limited (NYSE American: VNRX) said it has entered a collaboration with Sysmex (TYO: 6869) to optimize Volition’s Nu.Q® NETs H3.1 assay on the Sysmex platform. Volition stated the optimization will focus on NETosis-related diseases after assay transfer. The company cited a $3.8 billion total addressable market for the test.

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 vnrx_ex101.htm FORM OF SECURITIES PURCHASE AGREEMENT vnrx_ex101.htm EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 7, 2026, between VolitionRx Limited, a Delaware corporation (the “ Company ”), and

H.C. Wainwright has reduced its price target for VolitionRx (NYSE:VNRX) to $1.00 from $1.50, citing an increased share count, while maintaining a Buy rating. The company reported a Q4 2025 revenue miss, coming in at $0.4 million against a projected $0.8 million, and a net loss of $6.3 million. Despite a weak financial health score and cash burn, InvestingPro's Fair Value analysis suggests the stock might be undervalued.

VolitionRx Limited filed an amendment to its annual report, providing detailed Part III information on directors, executive officers, governance, and compensation. The filing also clarifies a one-for-twenty reverse stock split effective April 28, 2026, which retroactively adjusts all share data. As of June 30, 2025, non-affiliate common stock had a market value of $72,909,373, and as of April 28, 2026, there were 8,087,955 common shares outstanding. CEO Cameron Reynolds' total 2025 compensation was $638,233.

Analyst Jason Kolbert from D. Boral Capital has maintained a 'Buy' rating for VolitionRX (VNRX) with an unchanged price target of $3.00 USD. This reiteration reflects consistent confidence in the company's prospects, with historical ratings showing a steady 'Buy' status. The average target price from 5 analysts is $2.06, suggesting a significant upside of 984.21% from the current price, while GuruFocus estimates a fair value of $1.40 for VNRX.

VolitionRX is a specialized firm in the laboratory technology and diagnostics sector focused on transitioning its scientific advancements into commercial success. Investors are looking for evidence that the company's diagnostic assays will be adopted within large-scale laboratory networks. The stock currently trades around $0.20, near its 52-week low, reflecting cautious investor sentiment amid high volatility and a year-to-date decline.